Meta-analysis: upper gastrointestinal tolerability of valdecoxib, a cyclooxygenase-2-specific inhibitor, compared with nonspecific nonsteroidal anti-inflammatory drugs among patients with osteoarthritis and rheumatoid arthritis (Q28218359)

From Wikidata

Jump to navigation Jump to search

scientific article (publication date: March 2005)

Language	Label	Description	Also known as
English	Meta-analysis: upper gastrointestinal tolerability of valdecoxib, a cyclooxygenase-2-specific inhibitor, compared with nonspecific nonsteroidal anti-inflammatory drugs among patients with osteoarthritis and rheumatoid arthritis	scientific article (publication date: March 2005)

Statements

scholarly article

0 references

1 reference

based on heuristic

inferred from title

Meta-analysis: upper gastrointestinal tolerability of valdecoxib, a cyclooxygenase-2-specific inhibitor, compared with nonspecific nonsteroidal anti-inflammatory drugs among patients with osteoarthritis and rheumatoid arthritis (English)

0 references

0 references

rheumatoid arthritis

1 reference

based on heuristic

inferred from title

author name string

G M Eisen

1

0 references

J L Goldstein

2

0 references

D B Hanna

3

0 references

D A Rublee

4

0 references

language of work or name

0 references

publication date

1 March 2005

0 references

Alimentary Pharmacology & Therapeutics

0 references

21

0 references

5

0 references

591-8

0 references

Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2005.02383.X

21 April 2017

4-[5-Methyl-3-phenylisoxazol-4-yl]- benzenesulfonamide, valdecoxib: a potent and selective inhibitor of COX-2

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2005.02383.X

21 April 2017

The gastrointestinal effects of nonselective NSAIDs and COX-2-selective inhibitors

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2005.02383.X

21 April 2017

Epidemiology of nonsteroidal anti-inflammatory drug-associated gastrointestinal injury

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02383.X

21 January 2018

Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02383.X

21 January 2018

Celecoxib versus diclofenac in the management of osteoarthritis of the knee

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02383.X

21 January 2018

Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02383.X

21 January 2018

Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02383.X

21 January 2018

Gastrointestinal tract complications of nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis. A prospective observational cohort study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02383.X

21 January 2018

Efficacy and safety of valdecoxib in treating the signs and symptoms of rheumatoid arthritis: a randomized, controlled comparison with placebo and naproxen

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02383.X

21 January 2018

Efficacy and safety of the COX-2 specific inhibitor valdecoxib in the management of osteoarthritis of the hip: a randomized, double-blind, placebo-controlled comparison with naproxen

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02383.X

21 January 2018

Sulfone COX-2 inhibitors increase susceptibility of human LDL and plasma to oxidative modification: comparison to sulfonamide COX-2 inhibitors and NSAIDs

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02383.X

21 January 2018

A comparison of the upper gastrointestinal mucosal effects of valdecoxib, naproxen and placebo in healthy elderly subjects

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02383.X

21 January 2018

Reduced incidence of upper gastrointestinal ulcer complications with the COX-2 selective inhibitor, valdecoxib

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02383.X

21 January 2018

Incidence of gastroduodenal ulcers associated with valdecoxib compared with that of ibuprofen and diclofenac in patients with osteoarthritis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02383.X

21 January 2018

Meta-analysis of dyspepsia and nonsteroidal antiinflammatory drugs

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02383.X

21 January 2018

Dyspepsia tolerability from the patients' perspective: a comparison of celecoxib with diclofenac

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02383.X

21 January 2018

Gastrointestinal tolerability of the selective cyclooxygenase-2 (COX-2) inhibitor rofecoxib compared with nonselective COX-1 and COX-2 inhibitors in osteoarthritis.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02383.X

21 January 2018

Identifiers

10.1111/J.1365-2036.2005.02383.X

0 references

0 references

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q28218359&oldid=1260404443"